Are you over 18 and want to see adult content?
More Annotations
The Momentum Reloadable Prepaid Card
Are you over 18 and want to see adult content?
Expansão da Consciência com Foco em Enriquecimento! — Instituto Marcos Trombetta
Are you over 18 and want to see adult content?
Equipment Rentals in Homer Glen IL | Party Rental in Chicagoland | Equipment Sales & Repair in the Chicagoland area
Are you over 18 and want to see adult content?
A complete backup of seguroviagem.srv.br
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of www.viva.ro/vedete-si-evenimente/stiri/concurentii-asia-express-3-paziti-de-bodyguardul-celor-de-la-metalli
Are you over 18 and want to see adult content?
A complete backup of www.soyfutbol.com/internacional/La-Liga-Simeone-califica-como-partidazo-el-Atletico-de-Madrid-vs-Valencia-2
Are you over 18 and want to see adult content?
A complete backup of thewire.in/film/love-aaj-kal-movie-review
Are you over 18 and want to see adult content?
A complete backup of timesofindia.indiatimes.com/tv/news/hindi/bigg-boss-13-shehnaz-watches-her-journey-on-the-show-says-bigg-bo
Are you over 18 and want to see adult content?
A complete backup of www.leggo.it/spettacoli/grande_fratello/grande_fratello_vip_2020_paola_di_benedetto_tradimento_federico_non
Are you over 18 and want to see adult content?
Text
* Important Safety
Information
* Prescribing Info/Patient Info* Instructions
for Use
For U.S. Healthcare Professionals only Toggle navigation MenuSearch
* Important Safety Information * Prescribing Information * Patient Information * Instructions for Use * RESPIMAT® Inhaler & Dosing * Symptom Control & Safety* Exacerbation Data
* Patient Support
* Samples
* For Patients
Your browser does not support HTML5 video. For U.S. Healthcare Professionals only * RESPIMAT® Inhaler & Dosing * Symptom Control & Safety* Exacerbation Data
* Patient Support
STIOLTO RESPIMAT
a COPD treatment with IMPORTANT SAFETY INFORMATION FOR STIOLTO RESPIMAT __CONTRAINDICATION
Use of a LABA, including STIOLTO RESPIMAT, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma. STIOLTO is contraindicated in patients with hypersensitivity to tiotropium, ipratropium (atropine derivatives), olodaterol, or any component of this product. In clinical trials and postmarketing experience with tiotropium, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported. Hypersensitivity reactions were also reported in clinical trials with STIOLTO. INDICATION FOR STIOLTO RESPIMAT__ STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray is a combination of tiotropium, an anticholinergic, and olodaterol, a long-acting beta2‑ adrenergic agonist (LABA), indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. IMPORTANT LIMITATIONS OF USE STIOLTO is NOT indicated to treat acute deterioration of COPD and is not indicated to treat asthma. WARNINGS AND PRECAUTIONS LABA as monotherapy (without an ICS), for asthma increases the risk of asthma-related death, and in pediatric and adolescent patients, increases the risk of asthma-related hospitalizations. Do not initiate STIOLTO in patients with acutely deteriorating COPD, which may be a life-threatening condition, or used as rescue therapy for acute symptoms. Acute symptoms should be treated with an inhaled short-acting beta2‑agonist. STIOLTO should not be used more often or at higher doses than recommended, or with other LABAs as an overdose may result. If immediate hypersensitivity reactions occur, such as urticaria, angioedema, rash, bronchospasm, anaphylaxis, or itching, discontinue STIOLTO at once and consider alternative treatment. Patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions toSTIOLTO.
If paradoxical bronchospasm occurs, discontinue STIOLTO immediately and institute alternative therapy. STIOLTO can produce a clinically significant cardiovascular effect in some patients, as measured by increases in pulse rate, systolic or diastolic blood pressure, and/or symptoms. If such effects occur, STIOLTO may need to be discontinued. Use caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, in patients with known or suspected prolongation of the QT interval, and in patients who are unusually responsive to sympathomimetic amines. Use with caution in patients with narrow-angle glaucoma. Instruct patients to contact a physician immediately if signs or symptoms of acute narrow-angle glaucoma develop. Use with caution in patients with urinary retention especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any of these signs or symptoms develop. Patients with moderate to severe renal impairment (creatinine clearance of <60 mL/min) should be monitored closely for anticholinergic side effects. Be alert to hypokalemia and hyperglycemia.ADVERSE REACTIONS
The most common adverse reactions with STIOLTO (>3% incidence and higher than an active control) were: nasopharyngitis, 12.4% (11.7%/12.6%), cough, 3.9% (4.4%/3.0%), and back pain, 3.6%(1.8%/3.4%).
DRUG INTERACTIONS
* Use caution if administering adrenergic drugs because sympathetic effects of olodaterol may be potentiated. * Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of olodaterol. * Use with caution in patients taking non–potassium-sparing diuretics, as the ECG changes and/or hypokalemia may worsen with concomitant beta-agonists. * The action of adrenergic agents on the cardiovascular system may be potentiated by monoamine oxidase inhibitors or tricyclic antidepressants or other drugs known to prolong the QTc interval. Therefore, STIOLTO should be used with extreme caution in patients being treated with these drugs. Use beta-blockers with caution as they not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in patients withCOPD.
* Avoid co-administration of STIOLTO with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects. STIOLTO is for oral inhalation only. The STIOLTO cartridge is only intended for use with the STIOLTORESPIMAT inhaler.
Inform patients not to spray STIOLTO into the eyes as this may cause blurring of vision and pupil dilation. CL-STO-100021 6.5.2019 Please see accompanying full Prescribing Information,
Patient Information
,
and Instructions for Use for STIOLTO RESPIMAT.__
* Privacy Notice
* Terms of Use
* Contact Us
* Site Map
Boehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the trademarks SPIRIVA®, RESPIMAT®, and STIOLTO® under license. Other referenced trademarks are owned by third parties. Use of this Site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Policy. This Site is intended for U.S. healthcare professionals only. Copyright ©2019, Boehringer Ingelheim Pharmaceuticals, Inc. Allrights reserved.
(11/19) PC‑US‑111690 LEAVING STIOLTOHCP.COM You are now leaving a Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) site. BIPI is not responsible for the way information is processed by sites linked to this one. Please review those sites' privacy policies and terms of use to understand how your information will be processed. Linking to any other site is at your own risk.Cancel Continue
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0